Health ❯ Healthcare ❯ Biotechnology

Clinical Trials

Drug Development Cancer Treatment Autoimmune Diseases Duchenne Muscular Dystrophy Obesity Treatments Neurological Disorders Antibody Therapies Muscular Dystrophy Pulmonary Sarcoidosis Immunotherapy VIASKIN® Peanut Patch Cancer Research Nanobodies Alzheimer's Disease Genetic Diseases Alcohol Use Disorder Drug Efficacy Dermatology Metabolic Diseases Diabetic Kidney Disease Frontotemporal Dementia Rare Diseases Cancer Therapy Pediatric Medicine Macrophage Therapy Phase 1 Studies Antisense Oligonucleotides AI in Medicine Inflammatory Bowel Disease Gene Therapy Eosinophilic Esophagitis

Clearmind’s AUD Candidate Meets Early Safety Goal as Shares Double

The non-hallucinogenic MEAI pill advanced past the dose-escalation safety gate.

DBV Technologies Files 2025 Annual Report, Extends Runway as 2026 Peanut Patch Filings Near

Sarepta Reports Early siRNA Data Showing Muscle Delivery as Shares Surge

Apogee to Report 52-Week Phase 2 Data for Zumilokibart in Atopic Dermatitis Today

Eupraxia Reports Early EoE Trial Data With Near‑Normal Tissue at Top Dose

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

JPMorgan Upgrades Recursion, Raises Target to $11 as Shares Surge on AI Drug Signals

MoonLake Faces Expanding Securities Suits as Lead-Plaintiff Deadline Nears

Enlivex Raises $212 Million to Build RAIN Token Treasury, Plans Matteo Renzi Board Appointment

Protara Reports Strong Interim Phase 2 Results for TARA-002 in Pediatric Lymphatic Malformations

MoonLake Investors Courted for Lead Role in SDNY Securities Case After SLK Trial Collapse

Alector Ends Latozinemab After Phase 3 Failure, Slashes Workforce

FDA Opens Door to Reconsider Capricor’s Duchenne Cell Therapy Based on HOPE-3 Data

AbbVie Extends Rinvoq U.S. Exclusivity to 2037 as AI Biotechs Move From Models to Medicines

ATyr’s Sarcoidosis Drug Fails Phase 3 Goal, Shares Plunge Over 80%